- Seasoned entrepreneurial founding team
- World class scientific team
About Us
Established in 2013, NuBiyota is a pioneer in next-generation microbiome drug development. NuBiyota holds an exclusive license to the groundbreaking research developed at the University of Guelph, and led by co-founder, Dr. Emma Allen-Vercoe (PhD).
Dr. Allen-Vercoe is a prominent researcher in her field, with 25 years of experience in gut microbiology, the microbiota and its influence on health and disease. Dr. Allen-Vercoe has led multiple studies, published numerous academic papers , and has developed cutting edge innovations in her areas of expertise.
NuBiyota employs a world-class group of scientists and is led by a seasoned management team with extensive management and business development experience in the healthcare industry.
Together this team has developed a novel platform and a pipeline of microbiome therapeutic composition candidates for use in the treatment of medical indications, currently undergoing clinical testing.
NuBiyota has entered a strategic collaboration with the Takeda Pharmaceutical Company for the development of NuBiyota’s Microbial Ecosystem Therapeutic products for gastroenterology (GI) indications.
NuBiyota carries out its research activities in its state-of-the-art labs in Guelph, ON, Canada and has established a GMP manufacturing site in Pearl River, NY, USA.
Collaboration with Takeda to develop drugs for GI indications; MET-2 Canada Ph1 initiation for rCDI (recurrent Clostridioides Difficile Infection) indication.
Readout of multiple studies in Canada including rCDI, Metabolic, initial PD-1 safety and engraftment and Depression/anxiety.
Transition from rectally-delivered live microbial suspension to orally-delivered lyophilized capsule.
GMP manufacturing in Pearl River, NY
IND approved for phase 2 study in the US in metabolic disease.
NuBiyota’s Pillars of Success
People
Performance
- Strategic collaborations
- Application of clinical data to identify disease correlations
Platform
- Advanced CMC platform
- Leverages proprietary IP
Partners
- Partner with Takeda for GI indications
- Open to partnering for additional indications
Pipeline
- Pipeline of microbiome consortium candidates across multiple indications
- Safety data from over 200 patients